title: [Long-term follow-up of childhood low-risk ALL patients treated with SCMC-ALL-2005 protocol].
abstract: OBJECTIVE
  To evaluate the long-term efficacy of SCMC-ALL-2005 protocol in treatment of low-risk childhood acute lymphoblastic leukemia (ALL).
  
  
  METHODS
  From May 1, 2005 to April 30, 2009, 387 patients enrolled into SCMC-ALL-2005 protocol. Based on the characteristics of cell morphology, immunology, cytogenetics and molecular biology and treatment response, 158 patients were fit into the low-risk treatment group. All the cases were registered in pediatric oncology network database (POND). The clinical characteristics and outcome were analyzed.
  
  
  RESULTS
  Until December 31, 2012, the 5-year event free survival (EFS) and overall survival (OS) is (77.76±3.37)% and (89.55±2.83)%, respectively. Median follow-up time is 5.33 y (3.75-7.70 y). Five patients (3.16%) died of complication, all of them were severe infections. Twenty-seven patients (17.09%) relapsed, including 13 bone marrow relapse (8.23%), 5 testis relapse (5.32% of boys, 2 of unilateral and 3 bilateral), 6 central nerve system relapse (CNS, 3.80%), 1 relapse in both bone marrow and CNS, 1 relapse in both bone marrow and testis, and 1 right ovary and fallopian tube relapse. Relapse is related to positive minimal residual disease. Two cases (1.27%) occurred second tumors, 4 patients (2.53%) gave up treatment in complete remission without special reasons.
  
  
  CONCLUSIONS
  The EFS and life quality of SCMC-ALL-2005 protocol in the treatment of childhood low-risk ALL is satisfactory. The treatment-related mortality rate is lower, and the long-term EFS is higher than that of XH-99 protocol.
authors.affiliation: Shanghai Children's Medical Center, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China.
authors.forename: Wen-ting
authors.initials: WT
authors.lastname: Hu
authors.forename: Hui-liang
authors.initials: HL
authors.lastname: Xue
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
authors.forename: Ci
authors.initials: C
authors.lastname: Pan
authors.forename: Shu-hong
authors.initials: SH
authors.lastname: Shen
authors.forename: Min
authors.initials: M
authors.lastname: Zhou
authors.forename: Qi-dong
authors.initials: QD
authors.lastname: Ye
authors.forename: Hua
authors.initials: H
authors.lastname: Jiang
authors.forename: Chang-ying
authors.initials: CY
authors.lastname: Luo
authors.forename: Yan-jing
authors.initials: YJ
authors.lastname: Tang
authors.forename: Jian-min
authors.initials: JM
authors.lastname: Wang
authors.forename: Long-jun
authors.initials: LJ
authors.lastname: Gu
authors.forename: Jing-yan
authors.initials: JY
authors.lastname: Tang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality*; D016896:Treatment Outcome